Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Neurocrine Biosciences
Biotech
Neurocrine-Takeda antidepressant hits main mark in phase 2 trial
Neurocrine has nabbed a phase 2 trial win after its oral drug reduced depression severity among adults who haven’t benefited from prior therapies.
Gabrielle Masson
Apr 23, 2024 10:44am
Double whammy for Neurocrine as Takeda, Xenon pacts fail
Nov 10, 2023 7:22am
Neurocrine's ph. 3 data set up 2024 hyperplasia drug submission
Oct 5, 2023 8:41am
Neurocrine's potential hyperplasia blockbuster scores ph. 3 win
Sep 12, 2023 10:18am
Neurocrine blows fresh wind in Voyager's sails with $175M payday
Jan 9, 2023 9:30am
Neurocrine's $45M bet goes 0 for 2 with rare epilepsy flop
Dec 7, 2022 7:20am